Kura Oncology appoints Jennifer Fulk as CFO and principal accounting officer

Kura Oncology, Inc.

Effective Sept 8, 2026, Jennifer Fulk appointed CFO, principal financial and principal accounting officer.
Fulk replaces Troy E. Wilson as CFO and Thomas Doyle as principal accounting officer.
Compensation: $550,000 base salary, up to 45% bonus, option for 450,000 shares, PSU for 173,438 shares.
Prior roles: CFO Soleno Therapeutics, COO/CFO 120Water, CFO Talkspace, 15+ years at Eli Lilly.
Severance includes 12-18 months salary, COBRA, and equity acceleration in change of control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.